The cellular aging of a group of cells called alveolar type 2 pneumocytes — which work to promote airway stability, and play a key role in lung repair after injury — may be responsible for driving pulmonary fibrosis (PF). That’s according to new findings from a team led by…
Those who follow my column know that one of my passions is cooking. It always has been. My wife, Susan, and I usually eat meals I prepare using little to no prepackaged ingredients. Dinner usually included wine for me. But what I can eat and drink changed on July…
The first patient has been enrolled in a Phase 3 clinical trial of Tyvaso (treprostinil) inhalation solution for patients with idiopathic pulmonary fibrosis (IPF), according to the therapy’s developer, United Therapeutics. Called TETON 2 (NCT05255991), the trial will evaluate the treatment’s efficacy against a placebo in about…
Learning to live with a chronic illness is the hardest thing I’ve ever done in my young adult life. It’s stressful mentally, financially, socially, and emotionally. That’s in addition to the difficult physical challenges. Sometimes that stress manifests in ways I’m not proud of. Since my diagnosis of idiopathic…
I have a weight problem. But the bigger problem is that no one believes that I don’t choose to be this way. I’m an overweight, middle-aged woman fighting pulmonary fibrosis (PF) and going through menopause. As such, it takes double the effort to lose weight — especially since…
How many times have you heard someone start a story with “before the pandemic”? It has become a common refrain for the past two-plus years. While my idiopathic pulmonary fibrosis (IPF) and a pandemic don’t make good bedfellows, they joined forces to eliminate one of our passions, travel. Before…
BenevolentAI has identified a new treatment target for idiopathic pulmonary fibrosis (IPF) that will be added to AstraZeneca’s therapeutic discovery portfolio. This is the third IPF target identified by the platform for the biopharmaceutical company following previous discoveries. Another AI-generated target for chronic kidney disease (CKD)…
The treatment candidate RXC007 demonstrated promising efficacy in easing fibrosis, or scarring, in mouse models of idiopathic pulmonary fibrosis (IPF) and other scarring-related conditions. In healthy human volunteers participating in a recently-completed Phase 1 trial, RXC007 displayed a good safety and pharmacological profile. Now, Redx Pharma, the company…
While working on today’s column, I considered writing about my birthday on Oct. 4. Then, a topic came to me quite unexpectedly. On Monday, Sept. 26, I had to go to the hospital. Since the pandemic began, I’ve been careful to avoid large crowds in enclosed spaces and to…
Dosing has begun in healthy volunteers in a Phase 1 clinical trial evaluating the safety and pharmacological properties of LASN01, an experimental therapy for pulmonary fibrosis and other diseases characterized by excessive tissue scarring, or fibrosis. “The initiation of this trial is an important milestone for Lassen and continues…
Get regular updates to your inbox.
